New Antibiotic Against Serious Infections - Receives First Approval in Europe

Baar, Switzerland, November 13 (ots/PRNewswire) -

- ZEVTERA(TM) A Broad-spectrum, Anti-MRSA Cephalosporin
Antibiotic to Treat Complicated Skin and Soft Tissue Infections
Approved in Switzerland

- Not for UK Media

Swissmedic, the Swiss agency for therapeutic products, has
approved ZEVTERA(TM) (ceftobiprole medocaril) for the treatment of
complicated skin and soft tissue infections, including diabetic foot
infections which have not spread to the bone.

Ceftobiprole is licensed from and co-developed with Basilea
Pharmaceutica Ltd. Janssen-Cilag will market ceftobiprole in
Switzerland under the trade name ZEVTERA(TM). Swiss based Basilea
Pharmaceutica Ltd will co-promote the drug in key European markets
and North America.

Ceftobiprole is the first, broad-spectrum, anti-MRSA
cephalosporin antibiotic with activity against a range of
difficult-to-treat Gram-positive and Gram-negative hospital- and
community-acquired pathogens including methicillin-resistant
Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa(1). In
clinical trials, ceftobiprole has demonstrated high cure rates in
patients with complicated skin infections, including those caused by
the potentially deadly MRSA.

Data from the European Antimicrobial Resistance Surveillance
System (EARSS) show that the prevalence of MRSA - a difficult to
treat cause of hospital-and- community acquired infections - while
varying considerably among countries, has been rising across Europe
for the past six years(2)

The use of ceftobiprole in adults for the treatment of
complicated soft tissue infections, including diabetic foot
infections which have not spread to the bone, is under regulatory
review in United States, Australia and in the European Union among
other countries. In Canada, ceftobiprole was launched in August 2008
under the trade name ZEFTERA.

About Complicated Skin Infections

Complicated skin and soft tissue infections are among the most
common infections in the hospital setting. Staphylococcus aureus is
the predominant pathogen in these infections. In recent years,
resistant strains, such as MRSA have become increasingly common and
have been associated with increased morbidity and mortality. New
broad-spectrum antibiotics that cover resistant bacteria such as
MRSA, but also clinically important and problematic Gram-negative
pathogens, address a high-unmet medical need in the treatment of
severe skin and soft tissue infections.

Patients with chronic wounds or those who have recently received
antibiotics may also be infected by Gram-negative pathogens. This is
frequently the case for diabetic patients with foot infections.
Adequate treatment of diabetic foot infections can require
hospitalization, surgery and broad-spectrum intravenous antibiotics.

About Ceftobiprole

Ceftobiprole, the first anti-MRSA cephalosporin to be approved,
is an intravenous antibiotic that belongs to the class of
antibacterial drugs known as cephalosporins, which are used to treat
serious infections caused by a broad range of bacteria, characterized
as Gram-negative and Gram-positive, based on a classification process
that is used to identify the specific type of bacteria.

Phase III clinical trials have demonstrated that ceftobiprole is
clinically efficacious against the following pathogens: Enterobacter
cloacae, Enterococcus faecalis, Proteus mirabilis, Staphylococcus
aureus, Staphylococcus epidermidis, Streptococcus agalactiae,
Streptococcus pyogenes, Escherichia coli, Klebsiella pneumonia and
Pseudomonas aeruginosa.

The Janssen-Cilag company have a long and successful track record
in developing and marketing treatments for a wide variety of
conditions such as infectious disease, HIV, pain management, fungal
infections, multiple myeloma, gastroenterological disorders,
epilepsy, Alzheimer's disease, schizophrenia, acute bipolar mania,
behavioural psychological symptoms of dementia, disruptive behaviour
disorders, and autism. More information can be found at
http://www.janssen-cilag.com. The Janssen-Cilag companies are part of
the Johnson & Johnson family of companies.

This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on current expectations of future events.
If underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from
Janssen-Cilag's expectations and projections. Risks and uncertainties
include general industry conditions and competition; economic
conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign health
care reforms and governmental laws and regulations; and trends toward
health care cost containment. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of
Johnson & Johnson's Annual Report on Form 10-K for the fiscal year
ended December 30, 2007. Copies of this Form 10-K, as well as
subsequent filings, are available online at http://www.sec.gov,
http://www.jnj.com or on request from Johnson & Johnson.
Janssen-Cilag does not undertake to update any forward-looking
statements as a result of new information or future events or
developments.

---------------------------------

(1) Pseudomonas aeruginosa, a gram-negative pathogen, causes a
variety of infectious diseases and is the most significant cause of
hospital acquired infections particularly in pre-disposed patients
with metabolic, haematologic, and malignant diseases.

(2) European Antimicrobial Resistance Surveillance System (EARSS)
2005 Annual Report. Available at: http://www.rivm.nl/en/

ots Originaltext: Janssen-Cilag
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information, please contact: Jennifer Tear, Tel:
+32-14-60-26-38, Pharmaceutical Communications EMEA, Turnhoutsweg 30,
B-2340 Beerse 2340 Belgium